Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors

Background. In recent years, oncology studies have focused on molecular targeted therapy, based on the development of numerous agents with a role in inhibiting the epidermal growth factor receptor (EGFR). When overexpressed, EGFR plays an extremely important role in the growth of certain tumour cell...

Descripción completa

Detalles Bibliográficos
Autores principales: POPA, CRISTINA-MARIA, IANOŞI, SIMONA LAURA, SĂFTOIU, ADRIAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical University Publishing House Craiova 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987476/
https://www.ncbi.nlm.nih.gov/pubmed/35444828
http://dx.doi.org/10.12865/CHSJ.47.04.06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987476/
https://www.ncbi.nlm.nih.gov/pubmed/35444828
http://dx.doi.org/10.12865/CHSJ.47.04.06

Ejemplares similares